Figure 1.

Trial profile. ^aParticipants could have multiple reasons for ineligibility. ^bThe most common reasons for not meeting inclusion criteria or meeting exclusion criteria are listed. All other reasons occurred in <1% of participants. ^cOf 919 screened participants, 543 (59%) had historical genotypic reports, 9 (2%) of whom were excluded because of major nucleoside reverse-transcriptase inhibitor (NRTI) resistance: 1 had M41L and D67N, 2 had M41L, and the remaining 6 each had a single mutation identified as M184I, K65R, K219E, K219Q, D67N, or L210W (post hoc analysis). ^dOne participant in the tenofovir alafenamide (TAF)–based regimen group was found to be taking a tenofovir disoproxil fumarate–based regimen at baseline and therefore was excluded from the safety population. ^eForty-four participants had missing week 96 human immunodeficiency virus type 1 (HIV-1) RNA data owing to the coronavirus disease 2019 pandemic (ie, discontinued or unable to attend week 96 site visit because of the pandemic). ^fProtocol deviations leading to exclusion from the per-protocol population; participants could have had ≥1 reason. Abbreviations: AEs, adverse events; ART, antiretroviral therapy; DTG/3TC, dolutegravir/lamivudine.